Cancer

Studies in mice characterized two immunotoxins that could help treat BCMA-expressing MM. The immunotoxins consist of the cytotoxic Pseudomonas aeruginosa exotoxin domain III linked to a BCMA-targeting Fab fragment or variable fragment. In a xenograft mouse model of MM, the Fab-based toxin eliminated tumors in 19 out of 19 mice, and the variable fragment-based toxin eliminated tumors in 22 of 22 treated mice, and both and increased survival compared with vehicle. In a second xenograft mouse model of MM, the variable fragment-based immunotoxin eliminated tumors in all seven treated mice. Next steps include additional preclinical testing of the immunotoxins in models of MM.

GlaxoSmithKline plc has J6M0-mcMMAF (2857916; GSK2857916), an antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-BCMA antibody and monomethyl auristatin F, in Phase II to treat MM...